针对心肌梗塞治疗的先进纳米医学方法
Lin Song1, Kangwei Jia1, Fuqing Yang1
1School of Basic Medicine, Qingdao University, Qingdao, People's Republic of China.
International journal of nanomedicine
|July 2, 2024
概括
纳米药物通过减少心脏损伤和改善心脏功能来治疗心肌梗塞 (MI) 是有前途的. 本综述强调了近期针对心脏病的纳米医学进展,重点关注各种治疗策略.
科学领域:
- 心血管医学 心血管医学
- 生物医学工程 生物医学工程
- 纳米技术纳米技术
背景情况:
- 心肌梗塞 (MI) 导致不可逆转的心肌细胞死亡和心力衰竭,目前的治疗具有高死亡率.
- 基于纳米材料的疗法为减少心脏病发作大小和促进心脏病发作后心脏病修复提供了一个有希望的途径.
- 大多数针对心脏病发作的纳米医学研究目前处于临床前阶段.
研究的目的:
- 审查心肌梗塞治疗纳米药物的最新进展 (2016年至今).
- 总结基于其治疗机制的纳米医学应用.
- 为心血管修复提供新兴纳米疗法的概述.
主要方法:
- 对治疗心脏病的纳米药物进行的临床前和早期临床研究的系统审查.
- 纳米药物根据治疗策略进行分类 (例如,抗心肌细胞死亡,新血管化,抗氧化剂).
- 分析用于心脏应用的纳米药物输送系统的最新进展.
主要成果:
- 在临床前模型中,纳米药物在减少心脏病发作大小和保持心脏功能方面表现出有效性.
- 目前正在探索各种纳米医学策略,包括针对炎症和心脏重塑的策略.
- 最近的发展表明,有可能改善药物输送和针对性治疗心脏病发作.
结论:
- 纳米医学具有显著的潜力,可以改善心肌梗塞的结果.
- 需要进一步的研究和临床翻译才能充分意识到纳米治疗对心脏修复的好处.
- 有针对性的纳米药物策略为治疗心脏病发作和预防心力衰竭提供了一个有希望的未来.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
419
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
419
Heart Failure Drugs: Inotropic Agents
564
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
564


